Co-morbidities

Giuseppe Rosano, Richard Henry P. Tiongco, Rungroj Krittayaphong, et al

HF 22: SCD Risk Protection for Newly Diagnosed HF Patients

José González-Costello,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

EP 54: 5 Trials that will change your practice: Review of ESC 21 with Dr Purvi Parwani

Ankur Kalra, ,

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Deepak L Bhatt, Harriette Van Spall,

Sitaramesh Emani , William T Abraham ,

Watch Now

Yassir Javaid,

Giuseppe Rosano, Richard Henry P. Tiongco, Rungroj Krittayaphong, et al

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

Watch Now

Stylianos Tzeis,

Watch Now

Carlos Juanatey,

ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Deepak L Bhatt, Harriette Van Spall,

EP 54: 5 Trials that will change your practice: Review of ESC 21 with Dr Purvi Parwani

Ankur Kalra, ,

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

AHA 2020 Discussion: The SOLOIST-WHF Study

Harriette Van Spall, Deepak L Bhatt,

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

HF 22: SCD Risk Protection for Newly Diagnosed HF Patients

José González-Costello,

Sitaramesh Emani , William T Abraham ,

About

Comorbidities frequently accompany chronic heart failure, contributing to increased morbidity and mortality, and an impaired quality of life. Extreme comorbidity is significantly more common in patients with chronic heart failure due to left ventricular systolic dysfunction. The efficient management of such complexity requires the integration of general and specialist expertise.

Media

Giuseppe Rosano, Richard Henry P. Tiongco, Rungroj Krittayaphong, et al

HF 22: SCD Risk Protection for Newly Diagnosed HF Patients

José González-Costello,

Andrew JS Coats, Stefan Anker,

Watch Now

Carlos Juanatey,

Watch Now

Stylianos Tzeis,

Watch Now

Yassir Javaid,

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Shelley Zieroth, , , et al

Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

EP 54: 5 Trials that will change your practice: Review of ESC 21 with Dr Purvi Parwani

Ankur Kalra, ,

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Deepak L Bhatt, Harriette Van Spall,

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Su Down,

AHA 2020 Discussion: The SOLOIST-WHF Study

Harriette Van Spall, Deepak L Bhatt,

ESC 2020: Commentary on the EMPEROR-Reduced Study — Dr Giuseppe Galati

Giuseppe Galati,

HFA 2020: Dapagliflozin and diuretic use in patients with HFrEF in DAPA-HF

Alice Jackson,

HFA 2020: Prospective analysis of DAPA-HF

DAPA-HF: A discussion with the trialist

John JV McMurray, Mikhail Kosiborod,

image

Felipe Martínez,

image

Lars H Lund,

Lars Lund - SGTL2i beyond diabetes

Lars H Lund,

HFA 2019: AMBER trial - Prof Patrick Rossignol

Patrick Rossignol,

HFA 2019: Dr Ilias Kanellos

Ilias Kanellos ,

Heart Failure 2019 Highlights

Andrew JS Coats,

Articles

Transvenous Phrenic Nerve Stimulation - A Novel Therapy for Central Sleep Apnoea in Heart Failure

Sitaramesh Emani

,

William T Abraham

,

Citation:

European Cardiology 2012;8(1):44-7

DOI:

https://doi.org/10.15420/ecr.2012.8.1.44
  • Views: Views 226
  • Downloads: Downloads 3